Loading…
← CockpitCompetitor Analysis › RAPP Rapport Therapeutics, Inc.Open in the cockpit ↗

Rapport Therapeutics, Inc.RAPPCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops precision neuroscience drugs targeting receptor-associated proteins for epilepsy and neurological pain.

Momentum laggard 10
Mkt cap
$1.39B
US dollars, full cap
Free float
60%
of shares outstanding
$/day
$29.2M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 12.0%
Hurdle
n/a
no reverse DCF
Next earnings
118 days
16 Mar 2027
Close · USD$23.40
1D-1.5%
1W-13.4%
1M-20.3%
3M-51.1%
6M-34.5%
YTD-22.9%
1Y-6.8%
ATR %8.7%
Beta1.28
52w lowhigh55.8% off high

What Rapport Therapeutics does

Develops precision neuroscience drugs targeting receptor-associated proteins for epilepsy and neurological pain.

Has no product on sale, so it funds trials with capital raised from investors, including a 2024 stock-market debut. Any revenue would start with approval of its lead epilepsy drug, or earlier from a licensing deal with a larger drugmaker.

Products and services

  • RAP-219 (focal epilepsy)

Customers

  • Neurologists (post-approval)

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Precision neuroscience drug discovery

What could go right

  • Pivotal trial data readouts
  • Large epilepsy/CNS market opportunity

What could go wrong

  • Clinical trial failure risk
  • Competitive CNS/epilepsy drug landscape

Moat: none (IP / patents). Novel receptor-associated-protein targeting approach spun from prior pharma research, but still clinical-stage.

Headquarters: Boston, Massachusetts, US · Founded: 2022 · Employees: 84

Named competitors

Rapport Therapeutics at a glance

Size Rapport Therapeutics (RAPP) is a United States Health Care company (Biotechnology) with a market value of $1.39B, the 2025th largest of 3,085 United States companies the cockpit tracks. Shares closed at $23.40 on 18 Nov 2026.

Performance Over six months the shares fell 34.5%, against -17.2% for the median peer and -2.2% for the United States market (cap-weighted) — 4th lowest of 19 in its peer set.

Growth The operating margin is -838.1% (peer median -178.1%).

Valuation It trades at 50.1× enterprise value to sales against a peer median of 21.3× (8th most expensive of 18).

Short interest Short interest is 6.7% of the free float (30 Oct 2026).

Next results Next results expected around 16 Mar 2027 (exchange calendar; dates can move).

Relative performance

7510012521 May 202621 Aug 202618 Nov 2026Peer median 80RAPP 64
Six months, rebased to 100: Rapport Therapeutics against the median of its 20 peers (local-currency closes).

Rapport Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$20.0M$0$0$0$0
Revenue growth—————
Gross profit$19.1M-$1.02M-$839,000-$112,000-$15,000
EBITDA-$167M-$124M-$82.2M-$36.1M-$10.4M
Net income-$150M-$111M-$78.3M-$34.8M-$10.7M
Free cash flow-$121M-$88.1M-$67.2M-$28.8M-$3.53M
Capital expenditure$333,000$616,000$2.40M$1.64M$284,000
Total debt$9.39M$11.5M$1.48M$2.15M$0

Quarterly statements and history in the cockpit →

Rapport Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-25%0%+25%+50%688185ANAB4588NTLAABSITYRAQURE688105NUVB688765NVAXMSB087010RAPP6-month return →1-month return →
Up and to the right = strong over both horizons. Rapport Therapeutics is the large dot.

Rapport Therapeutics competitors and peer comparison

Head to head with its named competitors (RAPP vs XENE)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Rapport Therapeutics RAPP$1.39B-34%n/a-838%50.1×n/a
Xenon Pharmaceuticals XENE$3.71B-31%-100%n/an/an/a

How Rapport Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Rapport Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureRAPPPeer medianRank in peer set
1-month return-20.3%-14.8%4th lowest of 21
6-month return-34.5%-17.2%4th lowest of 19
Distance from 52-week high-55.8%-46.1%6th lowest of 21
Operating margin-838.1%-178.1%5th lowest of 19
EV / Sales50.1×21.3×8th most expensive of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Rapport Therapeutics RAPPUnited States$1.39B-34%n/a-838%50.1×n/an/a
CanSino Biologics 688185.SSChina$1.38B0%+30%-4%6.6×n/an/a
AnaptysBio ANABUnited States$1.40B-22%+13%62%7.9×0.5%+25.6%
Oncolys BioPharma 4588.TJapan$1.37B+181%+1,749%-295%408.9×n/an/a
Intellia Therapeutics NTLAUnited States$1.37B-20%-8%-821%21.3×n/an/a
Absci ABSIUnited States$1.41B+65%-47%-9,155%835.7×n/an/a
Tyra Bioscience TYRAUnited States$1.35B-41%n/an/an/an/an/a
uniQure QUREUnited States$1.42B-17%+28%-1,027%65.4×n/an/a
Nanjing Vazyme Biotech 688105.SSChina$1.42B+25%+16%-5%4.9×39.4%-2.5%
Generate Biomedicines GENBUnited States$1.34B-20%+56%-737%31.7×n/an/a
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCRUnited States$1.44B-7%+13%-7%2.3×n/an/a
Nuvation Bio NUVBUnited States$1.34B-16%+654%-61%5.7×n/an/a
Wuhan Healthgen Biotechnology 688765.SSChina$1.46B-51%+90%-297%205.0×n/an/a
Zhuhai Trinomab Pharmaceutical 688806.SSChina$1.32Bn/a+238%-1,196%164.8×n/an/a
UroGen Pharma URGNUnited States$1.46B-1%+159%-12%6.3×n/an/a
Novavax NVAXUnited States$1.31B-14%-61%-17%2.4×n/an/a
Fujian Haixi Pharmaceuticals 2637.HKHong Kong$1.47B-32%+25%33%n/an/an/a
Taysha Gene Therapies TSHAUnited States$1.30B-27%-13%-2,998%170.1×n/an/a
Mesoblast MSB.AXAustralia$1.49B-17%+556%-43%12.8×n/an/a
Peptron 087010.KSSouth Korea$1.49B-68%-13%-488%359.6×n/an/a
TLC BioSciences 7924.TWOTaiwan$1.50Bn/an/an/an/an/an/a

Questions

Who are Rapport Therapeutics's main competitors?
Named competitors: UCB (private or unlisted), Xenon Pharmaceuticals (XENE). The cockpit's measured peer set (industry) also includes CanSino Biologics (688185.SS), AnaptysBio (ANAB), Oncolys BioPharma (4588.T), Intellia Therapeutics (NTLA), Absci (ABSI), Tyra Bioscience (TYRA).
Is Rapport Therapeutics expensive compared with its peers?
On ev / sales it trades at 50.1× against a peer median of 21.3×, 8th most expensive of 18 in its peer set.
How has Rapport Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -34.5% against -17.2% for the median peer; over one year -6.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.